Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533248 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| Succinic Acid SCHEMBL3872447 | 0.89 | ALDH1A1 (0.44) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| SCHEMBL7330520 | 0.88 | SLC22A6 (0.44) | ALDH1A1TSHREGLN1HSD17B10MEN1 | |
| Succinic Acid SCHEMBL9248660 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| SCHEMBL18007115 | 0.83 | FFAR3 (0.41) | ALDH1A1TSHREGLN1SMN1; SMN2LMNA | |
| Succinic Acid SCHEMBL3871268 | 0.83 | THRB (0.53) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| Succinic Acid SCHEMBL721623 | 0.83 | THRB (0.53) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| SCHEMBL23119151 | 0.83 | GLO1 (0.47) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| SCHEMBL21996294 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TSHREGLN1MAPTCYP2D6 | |
| SCHEMBL4869440 | 0.83 | CYP1A2 (0.47) | ALDH1A1TSHRMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656638-A2 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-116199579-A | Preparation method of 2-methyl dimethyl glutarate | 安徽华业香料股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115551960-A | Ink set, image recording method, and recorded matter | 富士胶片株式会社 | 2022-12-30 | — | — | CN | disclosed |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-08 | — | — | US | disclosed |
| CN-107257813-B | Block copolymers having surface active anchoring groups, compositions and methods thereof | AZ电子材料卢森堡有限公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-3259292-B1 | BLOCK COPOLYMERS WITH SURFACE-ACTIVE JUNCTION GROUPS, COMPOSITIONS AND PROCESSES THEREOF | AZ ELECTRONIC MAT LUXEMBOURG SARL (LU) | 2020-04-08 | — | — | EP | disclosed |
| EP-3524599-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-10259907-B2 | Block copolymers with surface-active junction groups, compositions and processes thereof | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.À R.L. (LU) | 2019-04-16 | — | — | US | disclosed |
| US-20180346449-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2018-12-06 | — | — | US | disclosed |
| CN-102906134-B | 2-methylene glutaric acid copolymer and method for producing same | NIPPON CATALYTIC CHEM IND | 2015-06-24 | — | — | CN | disclosed |
| EP-2784074-A1 | PYRAZOLE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-8846746-B2 | Pyrazole compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20130085132-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| CN-1117569-C | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-08-13 | — | — | CN | disclosed |
| CN-1143323-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-02-19 | — | — | CN | disclosed |
| US-3956358-A | GLUTARONITRILE, GLUTARIC ACID ESTER METAL COMPOUND CATALYST | HALCON INTERNATIONAL, INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346449-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | ALDH1A1 1200/4885TSHR 2282/4885EGLN1 3911/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | ALDH1A1 1200/4885TSHR 2282/4885EGLN1 3911/4885 |
| US-20130085132-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC34A1 | ALDH1A1 676/4885TSHR 2374/4885EGLN1 2673/4885 |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | ALDH1A1 1200/4885TSHR 2282/4885EGLN1 3911/4885 |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | ALDH1A1 846/4885TSHR 1507/4885EGLN1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.